Introduction: Chronic kidney disease (CKD) causes significant morbidity and mortality. Medical therapies can reduce the progression of disease by up to 50%. CKD is undiagnosed in the majority of people who have it, resulting in undertreatment. CKD Stewardship (CKD-S) aims to identify hospital inpatients with undiagnosed mid-stage to late-stage CKD with the goal of facilitating diagnosis and initiating guideline-based therapies.
Methods And Analysis: This prospective, multicentre, cohort study compares two models of care, CKD-S and standard care, for identification and management of CKD, across six public hospitals in metropolitan Sydney, Australia. CKD-S entails active case finding using the electronic medical record, with nephrologist outreach to admitting teams and kidney nurse provided patient education. Adult inpatients with an admission estimated glomerular filtration rate (eGFR)<45 mL/min/1.73 m and not known to a nephrologist will be eligible, excluding those with short life expectancy or advanced age (>80 years). Participants will be enrolled between 1 March 2024 and 1 March 2025. Baseline and demographic data will be collected after discharge from the hospital. Participants will be followed up 12 months after discharge using Pharmaceutical Benefits Schedule and Medical Benefits Schedule data, linked via the Australian Institute of Health and Welfare Hub. We will report the proportion of all adults admitted to the hospital who are not already known to a nephrologist, in which a diagnosis of stage 3b-5 CKD is recognised by the CKD-S intervention team, compared with standard care. We will then compare the proportion in each cohort who have an eGFR or urine albumin:creatinine ratio measured, are referred to a nephrologist, and are prescribed guideline-directed therapies over the 12 months following discharge from the hospital.
Ethics And Dissemination: The study has ethics approval from the Sydney Local Health District's Ethics Committee (Concord Hospital Zone). The results of the CKD-S study will be published in peer-reviewed journals and presented at academic conferences.
Trial Registration Number: ACTRN12624000452594.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883606 | PMC |
http://dx.doi.org/10.1136/bmjopen-2024-094554 | DOI Listing |
ESC Heart Fail
March 2025
Institute of Health Informatics Research, University College London, London, UK.
Aims: Atrial fibrillation (AF) is a frequent comorbidity in heart failure (HF). We analysed factors associated with new-onset atrial fibrillation in patients with heart failure using linked real-world UK data from primary and secondary care, along with findings from genome-wide association studies.
Methods And Results: Among 163 174 participants with a diagnosis of HF (January 1998 to May 2016) from Clinical Practice Research Datalink (CPRD) and Hospital Episodes Statistics (HES), 111 595 participants had no previous history of AF (mean age 76.
J Am Coll Cardiol
March 2025
Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins Medicine, Baltimore, Maryland, USA; American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas, USA. Electronic address:
Background: Cigarette smoking is a strong risk factor for cardiovascular harm.
Objectives: The study sought to explore the detailed relationships between smoking intensity, pack-years, and time since cessation with inflammation, thrombosis, and subclinical atherosclerosis markers of cardiovascular harm.
Methods: We included 182,364 participants (mean age 58.
Anal Chim Acta
May 2025
Department of Nephrology, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang, PR China. Electronic address:
The sensitive, efficient, and simultaneous assay of creatinine and urea in different body fluid is crucial for the daily detection and treatment of chronic kidney disease. Here, we exploited a versatile composite surface enhanced Raman scattering (SERS) substrate of polydimethylsiloxane (PDMS)-flower-like ZIF-67@Ag nanoparticles (NPs) based on simple in-situ growth and ion sputtering strategies. The plasmonic Ag NPs assembled on the three-dimensional anisotropic ZIF-67 matrix, facilitating numerous resonant electromagnetic "hotspots".
View Article and Find Full Text PDFCirc J
March 2025
Kawasaki Geriatric Medical Center, Kawasaki Medical School.
Background: Patients with both heart failure (HF) and chronic kidney disease (CKD) are often treated with renin-angiotensin-aldosterone system inhibitors (RAASi), but these drugs can cause hyperkalemia, which may lead to their reduction or discontinuation, resulting in the loss of their beneficial effects. Approaches to managing RAASi-induced hyperkalemia are discordant, so in this study we aimed to establish a cross-specialty consensus on the optimal approach to managing hyperkalemia in patients with HF and CKD.
Methods And Results: The study used a modified Delphi methodology.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
October 2024
Research for Genetic Epidemiology and Genomics, School of Public Health, Suzhou Medical College of Soochow University, Suzhou Jiangsu 215123, China.
Objectives: Osteoporosis is characterized by decreased bone mass and damaged bone microstructure, often leading to fragility fractures. Low bone mineral density is a key risk factor for fractures. Serum cystatin C (CysC), an endogenous marker of glomerular filtration rate, is negatively correlated with bone mineral density and may be a potential risk factor for osteoporosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!